Tin tức & Cập nhật

A real-world study presented at ASH 2024 shows that CD19 chimeric antigen receptor (CAR) T-cell therapy is highly effective and has an acceptable toxicity profile for individuals with transformed indolent non-Hodgkin lymphoma (tiNHL).

The addition of the CDK4/6 inhibitor palbociclib to anti-HER2 and endocrine therapy (ET) significantly improves progression-free survival (PFS) in patients with hormone receptor-positive, HER-positive (HR+, HER+) metastatic breast cancer (mBC) in the first-line setting, according to the results of the phase III AFT-38 PATINA trial.

The interim analysis of the AMPLIFY trial provides the first phase III evidence of fixed-duration therapy combining a second-generation Bruton tyrosine kinase inhibitor (BTKi) with venetoclax with or without anti-CD20 for treatment-naïve (TN) chronic lymphocytic leukaemia (CLL).

The first phase III trial of pirtobrutinib in haematologic malignancies to readout has demonstrated superiority over investigator's choice in delaying progression in pretreated chronic lymphocytic leukaemia or small lymphocytic lymphoma (CLL/SLL), with results from the BRUIN CLL-321 study first presented at ASH 2024.